Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and over
On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency (EMA) to…
COVID-19 | Diagnostics | NIH | Therapeutics
Depression, loneliness associated with increased hospitalization risk after COVID-19
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
WHO validated 11th vaccine for COVID-19
On May 19, 2022, WHO issued an emergency use listing (EUL) for CONVIDECIA, a vaccine manufactured by CanSino…
NIH announced antiviral drug development awards
On May 18, 2022, the U.S. National Institutes of Health announced it had awarded approximately $577 million to…
Labcorp received EUA for first non-prescription at-home collection kit for combined COVID-19, Fflu and RSV detection
On May 18, 2022, LabCorp announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and…
InteliSwabﾮ COVID-19 rapid test validated to detect Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants
On May 17, 2022, OraSure Technologies announced that its InteliSwabﾮ COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1,…
Pfizer and BioNTech granted U.S. EUA for booster dose of COVID-19 vaccine in children 5 through 11 years of age
On May 17, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration expanded emergency use authorization…
TGen worked with Arizona zoos and state and federal wildlife agencies to test wild animals for SARS-CoV-2
On May 16, 2022, working with state and federal wildlife agencies and private and public zoos across Arizona,…
Novavax filed for Emergency Use Authorization of COVID-19 vaccine in Taiwan
On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food…
WHO and Medicines Patent Pool announced agreement with NIH for COVID-19 health technologies
On May 12, 2022, WHOﾒs COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement…
Cepheid received Emergency Use Authorization for Xpertﾮ Xpress CoV-2 plus
On May 12, 2022, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
NIH licensed COVID-19 research tools and early-stage technologies to WHO program
On May 12, 2022, the U.S. National Institutes of Health announced that it had licensed 11 COVID-19 research…
Lucira filed for authorization of first-of-its-Kind COVID-19 & flu at-home molecular test
On May 11, 2022, Lucira Health announced that it had submitted a request to the U.S. Food and…
KPWHRI report supported value of COVID-19 drugs
On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high…
Lucira received CE Mark for both COVID-19 & flu and COVID-19 molecular tests
On May 9, 2022, Lucira Health announced that both its COVID-19 & Flu and COVID-19 molecular tests have…
Novavax submitted variations to expand Australian and New Zealand provisional approval of Nuvaxovid COVID-19 vaccine in Great Britain
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
Novavax’s COVID-19 vaccine Nuvaxovid arrived in Singapore
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
WHO reported 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021
On May 5, 2022, the World Health Organization (WHO) reported estimates that show the full death toll associated…
Sorrento announced full enrollment of phase I study of intranasal STI-9199 (COVISHIELD) against Omicron BA.2 and all variants of concern
On May 2, 2022, Sorrento announced its Phase I study of intranasal STI-9199 (COVISHIELDTM) had been fully enrolled…
Moderna finalized plan for long-term strategic partnership with the Government of Canada
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
Moderna filed to expand conditional Marketing Authorization for COVID-19 vaccine to include children six months to under six years in the EU
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
Moderna filed for authorization of Its COVID-19 vaccine in young children six months to under six years of age
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
Biotechnology | COVID-19 | FDA | Vaccine
Pfizer and BioNTech submitted application for U.S. EUA for COVID-19 vaccine booster dose in children 5 through 11 years of age
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
Veklury (Remdesivir) was first and only approved treatment for pediatric patients under 12 years of age with COVID-19
On Apr. 25, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental…
Novavax announced initiation of COVID-19 vaccine booster study in adolescents in phase 3 PREVENT-19 trial
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
WHO recommended Paxlovid for high-risk COVID patients
On Apr. 22, 2022, the World Health Organization (WHO) made a strong recommendation for nirmatrelvir and ritonavir, sold…
Cocrystal Pharma collaborated with the NIAID to evaluate COVID-19 protease inhibitors
On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and…
CureVac and GSKﾒs bivalent second-generation mRNA accine candidate shown to be highly effective against SARS-CoV-2 variants
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
Initial results from Novavax’ COVID-19-Influenza vaccine trial were first to show feasibility of combination vaccine
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…